8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 5, 2026·SEC
Zentalis Pharmaceuticals, Inc.(ZNTL)Earnings, Financials & Key Ratios
ZNTL•NASDAQ
Price updated Jun 11, 2026
AboutZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.Show more
- Revenue$0-100.0%
- EBITDA-$152M+19.9%
- Net Income-$137M+17.4%
- EPS (Diluted)-1.91+18.0%
- ROE-49.53%-15.7%
- ROIC-40.52%-13.2%
- Debt/Equity0.18+44.7%
ZNTL Key Insights
Zentalis Pharmaceuticals, Inc. (ZNTL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 95 (top 5%)
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ZNTL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZNTL Price & Volume
Zentalis Pharmaceuticals, Inc. (ZNTL) stock price & volume — 10-year historical chart
Loading chart...
ZNTL Growth Metrics
Zentalis Pharmaceuticals, Inc. (ZNTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.9%
Return on Capital
10 Years-58.96%
5 Years-51.75%
3 Years-51%
Last Year-48.51%
ZNTL Recent Earnings
Zentalis Pharmaceuticals, Inc. (ZNTL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 12, 2026EPS
$0.50
Est $0.49
-2.0%
Revenue
—
Q2 2026
Mar 26, 2026EPS
$0.49
Est $0.41
-19.5%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$0.37
Est $0.49
+24.5%
Revenue
—
Q3 2025
Aug 6, 2025EPS
$0.37
Est $0.56
+33.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.50vs $0.49-2.0% | — |
| Q2 2026 | Mar 26, 2026 | $0.49vs $0.41-19.5% | — |
| Q4 2025 | Nov 10, 2025 | $0.37vs $0.49+24.5% | — |
| Q3 2025 | Aug 6, 2025 | $0.37vs $0.56+33.9% | — |
Based on last 12 quarters of dataView full earnings history →
ZNTL Peer Comparison
Zentalis Pharmaceuticals, Inc. (ZNTL) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 31.73B | 149.23 | -25.08 | -83.22% | 0.10 | |||
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 AUPH | 2.04B | 15.85 | 7.66 | 20.38% | 99.97% | 64.48% | 0.13 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARVN | 457.46M | 7.09 | -5.54 | -0.3% | -247.54% | -44.39% | 0.02 | |
 PTGX | 7.06B | 109.79 | -53.56 | -89.41% | -6.48% | -17.76% | 0.02 |
Compare ZNTL vs Peers
Zentalis Pharmaceuticals, Inc. (ZNTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZNTL Income Statement
Zentalis Pharmaceuticals, Inc. (ZNTL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 14K | 0 | 0 | 0 | 0 | 0 | 67.42M | 0 | 0 |
Revenue Growth % | - | -100% | - | - | - | - | - | -100% | -100% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 151K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 14K▲ 0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 67.42M▲ 0% | 0▼ 100.0% | -151K▲ 0% |
Gross Margin % | 100% | - | - | - | - | - | 100% | - | - |
Gross Profit Growth % | - | -100% | - | - | - | - | - | -100% | - |
Operating Expenses | 23.8M | 46.84M | 118.79M | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M | 144.89M |
OpEx % of Revenue | 169978.57% | - | - | - | - | - | 383.57% | - | - |
Selling, General & Admin | 4.88M | 8.46M | 33.89M | 40.94M | 54.55M | 59.4M | 87.11M | 37.72M | 34.97M |
SG&A % of Revenue | 34828.57% | - | - | - | - | - | 129.2% | - | - |
Research & Development | 18.92M | 38.39M | 84.9M | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M | 108.76M |
R&D % of Revenue | 135150% | - | - | - | - | - | 248.82% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 4.95M | 3.74M | 7.8M | 1000K |
Operating Income | -23.78M▲ 0% | -46.84M▼ 97.0% | -118.79M▼ 153.6% | -216.54M▼ 82.3% | -227.29M▼ 5.0% | -299.51M▼ 31.8% | -191.19M▲ 36.2% | -152.81M▲ 20.1% | -145.04M▲ 0% |
Operating Margin % | -169878.57% | - | - | - | - | - | -283.57% | - | - |
Operating Income Growth % | - | -96.97% | -153.57% | -82.29% | -4.96% | -31.78% | 36.16% | 20.08% | - |
EBITDA | -23.73M | -46.73M | -118.63M | -216M | -225.86M | -298.12M | -189.91M | -152.07M | -144.41M |
EBITDA Margin % | -169510.78% | - | - | - | - | - | -281.65% | - | - |
EBITDA Growth % | - | -96.93% | -153.83% | -82.08% | -4.57% | -31.99% | 36.3% | 19.92% | 31.5% |
D&A (Non-Cash Add-back) | 51.49K | 111K | 160K | 544K | 1.43M | 1.39M | 1.29M | 739K | 628K |
EBIT | -23.78M | -46.84M | -118.79M | -207.74M | -227.29M | -248.99M | -187.46M | -145.01M | -136.84M |
Net Interest Income | 355K | 498K | 0 | 0 | -2.57M | 0 | 0 | 0 | 0 |
Interest Income | 355K | 498K | 0 | 0 | 2.26K | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 2.58M | 0 | 0 | 0 | 0 |
Other Income/Expense | 355K | 482K | 683K | 50.15M | -10.29M | 6.6M | 25.5M | 16.19M | 21.47M |
Pretax Income | -23.43M▲ 0% | -46.36M▼ 97.9% | -118.1M▼ 154.7% | -166.39M▼ 40.9% | -237.58M▼ 42.8% | -292.91M▼ 23.3% | -165.69M▲ 43.4% | -136.62M▲ 17.5% | -123.57M▲ 0% |
Pretax Margin % | -167342.86% | - | - | - | - | - | -245.74% | - | - |
Income Tax | 4K | 15K | 444K | -297K | -469K | -601K | 177K | 442K | 562K |
Effective Tax Rate % | -0.02% | -0.03% | -0.38% | 0.18% | 0.2% | 0.21% | -0.11% | -0.32% | -0.45% |
Net Income | -21.07M▲ 0% | -45.66M▼ 116.8% | -117.84M▼ 158.1% | -158.72M▼ 34.7% | -236.81M▼ 49.2% | -292.19M▼ 23.4% | -165.84M▲ 43.2% | -137.06M▲ 17.4% | -124.13M▲ 0% |
Net Margin % | -150478.57% | - | - | - | - | - | -245.96% | - | - |
Net Income Growth % | - | -116.75% | -158.07% | -34.69% | -49.19% | -23.39% | 43.24% | 17.35% | 44.63% |
Net Income (Continuing) | -23.43M | -46.38M | -118.55M | -166.09M | -237.11M | -292.31M | -165.87M | -137.06M | -124.13M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 7.54M | 6.82M | 24.8M | 528K | 221K | 107K | 0 | 0 | 0 |
EPS (Diluted) | -1.17▲ 0% | -1.29▼ 10.3% | -2.87▼ 122.5% | -3.72▼ 29.6% | -4.48▼ 20.4% | -4.47▲ 0.2% | -2.33▲ 47.9% | -1.91▲ 18.0% | -1.77▲ 0% |
EPS Growth % | - | -10.26% | -122.48% | -29.62% | -20.43% | 0.22% | 47.87% | 18.03% | 44.9% |
EPS (Basic) | -1.17 | -1.29 | -2.87 | -3.72 | -4.48 | -4.47 | -2.33 | -1.91 | - |
Diluted Shares Outstanding | 18.06M | 35.88M | 41.04M | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M | 70.26M |
Basic Shares Outstanding | 18.06M | 35.88M | 41.04M | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M | 70.26M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ZNTL Balance Sheet
Zentalis Pharmaceuticals, Inc. (ZNTL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 26.68M | 68.89M | 345.1M | 350.77M | 451.93M | 496.72M | 386.07M | 253.19M | 218.1M |
Cash & Short-Term Investments | 25.15M | 67.25M | 338.5M | 340.13M | 437.37M | 482.92M | 371.08M | 245.89M | 211.76M |
Cash Only | 25.15M | 67.25M | 54.95M | 59.96M | 43.07M | 28.04M | 33.9M | 35.99M | 31.93M |
Short-Term Investments | 0 | 0 | 283.55M | 280.17M | 394.3M | 454.88M | 337.18M | 209.9M | 179.83M |
Accounts Receivable | 917K | 140K | 0 | 2.63M | 0 | 0 | 5M | 1.93M | 0 |
Days Sales Outstanding | 23.91K | - | - | - | - | - | 27.07 | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 417K | 0 | 14.56M | 13.8M | 0 | 5.37M | 6.34M |
Total Non-Current Assets | 14.32M | 19.34M | 20.45M | 121.25M | 101.52M | 65.31M | 44.27M | 35.78M | 34.97M |
Property, Plant & Equipment | 260K | 2.84M | 3.62M | 52.84M | 50.08M | 41.73M | 37.23M | 29.04M | 28.25M |
Fixed Asset Turnover | 0.05x | - | - | - | - | - | 1.81x | - | 0.00x |
Goodwill | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | 0 | 0 | 0 |
Intangible Assets | 8.8M | 8.8M | 8.8M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | -46.26K | 243K | 0 | 40.12M | 23.84M | 2.68M | 0 | 0 | 0 |
Other Non-Current Assets | 1.52M | 2.97M | 4.3M | 7.04M | 9.72M | 6.82M | 7.04M | 6.74M | 6.72M |
Total Assets | 41M▲ 0% | 88.23M▲ 115.2% | 365.56M▲ 314.3% | 472.02M▲ 29.1% | 553.46M▲ 17.3% | 562.03M▲ 1.5% | 430.34M▼ 23.4% | 288.97M▼ 32.9% | 253.07M▲ 0% |
Asset Turnover | 0.00x | - | - | - | - | - | 0.16x | - | 0.00x |
Asset Growth % | - | 115.21% | 314.31% | 29.13% | 17.25% | 1.55% | -23.43% | -32.85% | -122.8% |
Total Current Liabilities | 6.21M | 14.9M | 28.6M | 43.94M | 56.65M | 69.37M | 52.73M | 36.56M | 35.24M |
Accounts Payable | 3.43M | 4.29M | 8.66M | 11.59M | 11.25M | 14.93M | 7.44M | 7.21M | 7.38M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | 15.31K |
Short-Term Debt | 0 | 781K | 0 | 1.45M | 2.16M | 2.62M | 0 | 3.87M | 0 |
Deferred Revenue (Current) | 223.42K | 0 | 0 | 0 | 0 | 281K | 0 | 0 | 0 |
Other Current Liabilities | 223K | 6.85M | 410K | 20.68M | 43.24M | -2.9M | 0 | 25.28M | 27.86M |
Current Ratio | 4.30x | 4.62x | 12.07x | 7.98x | 7.98x | 7.16x | 7.32x | 6.93x | 6.19x |
Quick Ratio | 4.30x | 4.62x | 12.07x | 7.98x | 7.98x | 7.16x | 7.32x | 6.93x | 6.19x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 2.48M | 4.91M | 3.58M | 63.6M | 62.79M | 55.27M | 40.43M | 36.2M | 35.15M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.65M |
Capital Lease Obligations | 0 | 1.7M | 1.1M | 44.46M | 45.17M | 43.15M | 39.58M | 35.7M | 110.1M |
Deferred Tax Liabilities | 2.46M | 3.21M | 0 | 19.14M | 15M | 10.34M | 0 | 0 | 0 |
Other Non-Current Liabilities | 21K | 5K | 2.48M | 0 | 2.62M | 1.78M | 849K | 500K | 500K |
Total Liabilities | 8.69M | 19.81M | 32.18M | 107.54M | 119.43M | 124.64M | 93.15M | 72.76M | 70.39M |
Total Debt | 0 | 2.48M | 2M | 45.91M | 47.33M | 45.77M | 42.65M | 39.58M | 34.65M |
Net Debt | -25.15M | -64.77M | -52.95M | -14.04M | 4.26M | 17.73M | 8.75M | 3.58M | 2.72M |
Debt / Equity | - | 0.04x | 0.01x | 0.13x | 0.11x | 0.10x | 0.13x | 0.18x | 0.19x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.24x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.02x |
Interest Coverage | - | - | - | - | -88.27x | - | - | - | - |
Total Equity | 32.31M▲ 0% | 68.42M▲ 111.8% | 333.38M▲ 387.2% | 364.48M▲ 9.3% | 434.02M▲ 19.1% | 437.39M▲ 0.8% | 337.19M▼ 22.9% | 216.2M▼ 35.9% | 182.68M▲ 0% |
Equity Growth % | - | 111.79% | 387.24% | 9.33% | 19.08% | 0.78% | -22.91% | -35.88% | -130.92% |
Book Value per Share | 1.79 | 1.91 | 8.12 | 8.54 | 8.21 | 6.69 | 4.74 | 3.01 | 2.60 |
Total Shareholders' Equity | 24.77M | 61.6M | 308.58M | 363.95M | 433.8M | 437.28M | 337.19M | 216.2M | 182.68M |
Common Stock | 2.27M | 2.89M | 41K | 45K | 59K | 70K | 71K | 69K | 71K |
Retained Earnings | -37.33M | -82.99M | -200.83M | -359.56M | -596.37M | -888.56M | -1.05B | -1.19B | -1.23B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -56K | 0 | 36K | -125K | -1.35M | 2.19M | 558K | 196K | -50K |
Minority Interest | 7.54M | 6.82M | 24.8M | 528K | 221K | 107K | 0 | 0 | 0 |
ZNTL Cash Flow Statement
Zentalis Pharmaceuticals, Inc. (ZNTL) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -24.25M | -39.14M | -86.83M | -154.09M | -163.75M | -207.82M | -170.86M | -125.25M | -125.57M |
Operating CF Margin % | -173221.43% | - | - | - | - | - | -253.41% | - | - |
Operating CF Growth % | - | -61.41% | -121.81% | -77.48% | -6.27% | -26.91% | 17.79% | 26.7% | 61.1% |
Net Income | -23.43M | -46.38M | -118.55M | -166.09M | -237.11M | -292.19M | -165.87M | -137.06M | -124.13M |
Depreciation & Amortization | 51K | 111K | 160K | 544K | 1.43M | 1.39M | 1.29M | 739K | 628K |
Stock-Based Compensation | 308K | 617K | 23.15M | 35.74M | 46.84M | 54.82M | 67.27M | 20.72M | 14.24M |
Deferred Taxes | 2.37M | 0 | 17K | -2.51M | -769K | -853K | 0 | 0 | 0 |
Other Non-Cash Items | -2.37M | 0 | 556K | -38.38M | 12.61M | 23.15M | -57.01M | -526K | -4.69M |
Working Capital Changes | -1.18M | 6.51M | 7.84M | 16.61M | 13.25M | 5.86M | -16.54M | -9.12M | -11.6M |
Change in Receivables | -254K | 777K | -277K | 413K | 0 | 0 | -5M | 5M | 0 |
Change in Inventory | -1.86M | 0 | -5.52M | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 977K | 7.12M | 14.31M | 13.96M | 15.53M | 10.92M | -18.02M | -17.32M | -12.77M |
Cash from Investing | -227K | -352K | -284.83M | -18.11M | -114.18M | -44.46M | 176.56M | 131.62M | 121.16M |
Capital Expenditures | -227K | -352K | -758K | -6.11M | -2.55M | -583K | -221K | 0 | -34K |
CapEx % of Revenue | 1621.43% | - | - | - | - | - | 0.33% | - | - |
Acquisitions | 0 | 0 | 18.42M | -14.32M | 111.63K | 0 | 65K | 0 | 1.13M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -18.42M | 0 | -111.63K | 0 | 0 | 698K | -440K |
Cash from Financing | 9.47M | 81.83M | 360.44M | 178.52M | 261.04M | 237.3M | 108K | -4.28M | -5.59M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 9.47M | 81.88M | 342.01M | 179.67M | 261.04M | 237.3M | 349K | -4.28M | -4.14M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -46K | 18.42M | -1.15M | 0 | 0 | -241K | 0 | -1.45M |
Net Change in Cash | -15.01M▲ 0% | 42.34M▲ 382.1% | -11.22M▼ 126.5% | 6.31M▲ 156.3% | -16.89M▼ 367.5% | -14.98M▲ 11.3% | 5.81M▲ 138.8% | 2.09M▼ 64.0% | -10M▲ 0% |
Free Cash Flow | -24.48M▲ 0% | -39.49M▼ 61.3% | -87.58M▼ 121.8% | -160.2M▼ 82.9% | -166.3M▼ 3.8% | -208.41M▼ 25.3% | -171.08M▲ 17.9% | -125.25M▲ 26.8% | -125.6M▲ 0% |
FCF Margin % | -174842.86% | - | - | - | - | - | -253.74% | - | - |
FCF Growth % | - | -61.35% | -121.76% | -82.91% | -3.81% | -25.32% | 17.91% | 26.79% | 17.21% |
FCF per Share | -1.36 | -1.10 | -2.13 | -3.75 | -3.15 | -3.19 | -2.41 | -1.74 | -1.79 |
FCF Conversion (FCF/Net Income) | 1.15x | 0.86x | 0.74x | 0.97x | 0.69x | 0.71x | 1.03x | 0.91x | 1.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 4K | 15K | 18K | 20K | 12K | 140K | 359K | 0 | 0 |
ZNTL Key Ratios
Zentalis Pharmaceuticals, Inc. (ZNTL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -90.67% | -58.66% | -45.49% | -59.31% | -67.06% | -42.82% | -49.53% | -53.61% |
| Return on Invested Capital (ROIC) | -650.44% | -62.72% | -51.49% | -43.23% | -50.29% | -35.8% | -40.52% | -46.77% |
| Gross Margin | - | - | - | - | - | 100% | - | - |
| Net Margin | - | - | - | - | - | -245.96% | - | - |
| Debt / Equity | 0.04x | 0.01x | 0.13x | 0.11x | 0.10x | 0.13x | 0.18x | 0.19x |
| Interest Coverage | - | - | - | -88.27x | - | - | - | - |
| FCF Conversion | 0.86x | 0.74x | 0.97x | 0.69x | 0.71x | 1.03x | 0.91x | 1.01x |
| Revenue Growth | -100% | - | - | - | - | - | -100% | -100% |
Related:ZNTL Dividend History·ZNTL Revenue History·ZNTL Price History·ZNTL P/E History·ZNTL Financial Ratios·ZNTL Institutional Holders
ZNTL SEC Filings & Documents
Zentalis Pharmaceuticals, Inc. (ZNTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZNTL Frequently Asked Questions
Zentalis Pharmaceuticals, Inc. (ZNTL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zentalis Pharmaceuticals, Inc. (ZNTL) saw revenue decline by 100.0% over the past year.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $124.1M for fiscal year 2025.
Dividend & Returns
Zentalis Pharmaceuticals, Inc. (ZNTL) has a return on equity (ROE) of -49.5%. Negative ROE indicates the company is unprofitable.
Zentalis Pharmaceuticals, Inc. (ZNTL) had negative free cash flow of $125.6M in fiscal year 2025, likely due to heavy capital investments.